US-based VeraLight, backed by US-based industrial group Dow Chemical and US-based life science instruments business InLight Solutions, has raised $200k in debt, rights and securities.
VeraLight, a company which uses fluorescent lights instead of blood tests to screen patients for diabetes, has raised $200k in debt, rights and securities, according to a recent filing
A June filing showed the company receiving $2.5m toward a $4.1m round of equity, debt, rights and securities.
VeraLight has raised a total of $37.5m to date from US-based industrial group Dow Chemical and US-based life science instruments business InLight Solutions as well as venture firms CMEA Capital, Epic…
